Horizon Space II (HSPT) sponsor exits after SL Science business combination

Rhea-AI Filing Summary

Horizon Space Acquisition II Sponsor Corp. and Mingyu Li have filed Amendment No. 1 to their Schedule 13D to report that they no longer own any shares of Horizon Space Acquisition II Corp. (HSPT). The cover pages show 0 shares beneficially owned and 0% of the ordinary share class.

The change follows the June 12, 2026 business combination in which HSPT and SL Bio Ltd. became subsidiaries of SL Science Holding Limited (PubCo). In that transaction, each HSPT ordinary share was cancelled and exchanged for one PubCo ordinary share, and the sponsor ceased to hold any HSPT securities. This amendment is characterized as a final, "exit" filing for the reporting persons.

Insights

SPAC and M&A governance analyst

Filing records sponsor’s formal exit from HSPT after merger.

This amendment shows Horizon Space Acquisition II Sponsor Corp. and Mingyu Li now report 0 beneficial ownership and 0% of HSPT’s ordinary shares. The shift stems from completion of the business combination with SL Science Holding Limited and related merger steps.

Each HSPT unit was separated, rights converted into ordinary shares, and then all HSPT ordinary shares were cancelled for PubCo ordinary shares. As a result, HSPT became a PubCo subsidiary and the sponsor’s stake moved out of HSPT, prompting this final, exit Schedule 13D amendment. The filing mainly updates disclosure rather than introducing new economics.

Key Figures

Beneficial ownership (Sponsor): 0.00 shares Beneficial ownership (Mingyu Li): 0.00 shares Percent of class (Sponsor): 0% +3 more

6 metrics

Beneficial ownership (Sponsor) 0.00 shares Horizon Space Acquisition II Sponsor Corp. after amendment

Beneficial ownership (Mingyu Li) 0.00 shares Mingyu Li after amendment

Percent of class (Sponsor) 0% Ordinary Shares of HSPT after business combination

Percent of class (Mingyu Li) 0% Ordinary Shares of HSPT after business combination

Business combination closing date June 12, 2026 Consummation of Business Combination Agreement

Business Combination Agreement date May 9, 2025 Agreement among HSPT, SL Bio Ltd. and related entities

Key Terms

Business Combination Agreement, beneficially own, dispositive power, Securities Purchase Agreement, +2 more

6 terms

Business Combination Agreement financial

"On June 12, 2026, HSPT consummated the previously announced business combination pursuant to the Business Combination Agreement, dated as of May 9, 2025"

A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.

beneficially own financial

"This Amendment is being filed because the Reporting Persons no longer beneficially own any Ordinary Shares of HSPT"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

dispositive power financial

"Mr. Li is the sole director of the Sponsor, beneficially owns 50% ... and has voting and dispositive power over securities held by the Sponsor"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Securities Purchase Agreement financial

"10.1 Securities Purchase Agreement by and among the Registrant and the sponsor, dated as of July 25, 2024"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Securities Transfer Agreement financial

"10.2 Securities Transfer Agreement, among the Registrant, the sponsor and the directors, dated as of July 26, 2024"

Private Units Subscription Agreement financial

"10.4 Private Units Subscription Agreement dated November 14, 2024 between the Sponsor and the Issuer."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/17/2026 - 06:04 PM Accepted by SEC EDGAR 06/17/2026 - 06:03 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Horizon Space Acquisition II Corp.

(Name of Issuer)

Ordinary Share, par value $0.0001 per share

(Title of Class of Securities)

G4627B103

(CUSIP Number)

Mingyu Li
1412 Broadway, 21st Floor, Suite 21V
New York, NY, 10018
646-257-5537

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): G4627B103

1

Name of reporting person

Horizon Space Acquisition II Sponsor Corp.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP Number(s): G4627B103

1

Name of reporting person

Mingyu Li

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Share, par value $0.0001 per share
(b)	Name of Issuer: Horizon Space Acquisition II Corp.
(c)	Address of Issuer's Principal Executive Offices: 1412 BROADWAY, 21ST FLOOR, SUITE 21V, NEW YORK, NEW YORK , 10018.
Item 1 Comment: This amendment No. 1 (the "Amendment") to the Schedule 13D is being filed to amend and supplement the statement on Schedule 13D, initially filed with the Securities and Exchange Commission (the "SEC") on November 19, 2024 ( the "Schedule 13D"). This Amendment relates to Horizon Space Acquisition II Sponsor Corp., a Cayman Islands exempted company and sponsor (the "Sponsor") of Horizon Space Acquisition II Corp. (the "Issuer" or "HSPT"), and Mr. Mingyu Li (together with the Sponsor, the "Reporting Persons"), and the ordinary shares, par value $0.0001 per share, of HSPT (the "Ordinary Shares"). Mr. Li is the sole director of the Sponsor, beneficially owns 50% of the issued and outstanding shares of the Sponsor and has voting and dispositive power over securities held by the Sponsor. This Amendment is being filed because the Reporting Persons no longer beneficially own any Ordinary Shares of HSPT (the Sponsor had been the holder of record of the Ordinary Shares previously reported on Schedule 13D). Therefore, this Amendment constitutes the final amendment to the Reporting Persons' Schedule 13D and an "exit" filing for the Reporting Persons.
Item 2.	Identity and Background
(a)	This statement is filed by the Sponsor and Mr. Mingyu Li.
(b)	The principal business address of the Sponsor is c/o Horizon Space Acquisition II Corp., 1412 Broadway, 21st Floor, Suite 21V, New York, NY 10018. The principal business address of Mr. Li is c/o Horizon Space Acquisition II Corp., 1412 Broadway, 21st Floor, Suite 21V, New York, NY 10018.
(c)	The Sponsor is the sponsor of the Issuer and primarily involved in investment. Mr. Li beneficially owns 50% issued and outstanding shares of the Sponsor. In accordance with the governing documents of the Sponsor, Mr. Li is the sole director of the Sponsor and deemed to have the voting and dispositive rights over the securities of us held by the Sponsor.
(d)	During the past five years, none of the Reporting Persons or to the knowledge of the Reporting Persons, the persons identified in this Item 2, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was the subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal and state securities laws of findings any violation with respect to such laws.
(e)	During the past five years, none of the Reporting Persons or to the knowledge of the Reporting Persons, the persons identified in this Item 2, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(f)	The Sponsor is a exempted company incorporated in Cayman Islands. Mr. Li is a citizen of the People's Republic of China.
Item 3.	Source and Amount of Funds or Other Consideration
	The information set forth in Items 4 and 5 of this Schedule 13D are hereby incorporated by reference into this Item 3.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is amended and supplemented as follows: Consummation of the Business Combination On June 12, 2026, HSPT consummated the previously announced business combination pursuant to the Business Combination Agreement, dated as of May 9, 2025 ( the "Business Combination Agreement"), with SL Science Holding Limited, a Cayman Islands exempted company ("PubCo"), CW Mega Limited, a Cayman Islands exempted company and a wholly-owned subsidiary of PubCo ("Merger Sub I"), WW Century Limited, a Cayman Islands exempted company and a wholly-owned subsidiary of PubCo ("Merger Sub II"), and SL Bio Ltd., a Cayman Islands exempted company limited by shares ("SL Bio"). Pursuant to the Business Combination Agreement, (i) Merger Sub I merged with and into HSPT, with HSPT as the surviving entity and a wholly-owned subsidiary of PubCo (the "First Merger"), and (ii) following the First Merger, Merger Sub II merged with and into SL Bio, with SL Bio as the surviving entity and a wholly-owned subsidiary of PubCo (the "Second Merger," and together with the First Merger and the other transactions contemplated by the Business Combination Agreement, the "Business Combination"). Upon the consummation of the Business Combination, each of HSPT and SL Bio became a subsidiary of PubCo, and the shareholders of HSPT and SL Bio received ordinary shares of PubCo, par value $0.0001 per share ("PubCo Ordinary Shares"), as consideration and become shareholders of PubCo. Immediately prior to the First Merger Effective Time (as defined in the Business Combination Agreement), each HSPT Unit issued and outstanding was automatically detached, and the holder thereof was deemed to hold one (1) HSPT Ordinary Share and one (1) HSPT Right in accordance with the terms of the applicable unit (the "Unit Separation"). Each HSPT Right issued and outstanding was then automatically converted into one-tenth (1/10) of one HSPT Ordinary Share (the "Right Conversion"). Immediately following the Unit Separation and Right Conversion, each HSPT Ordinary Share (including those resulting from the Unit Separation and Right Conversion) issued and outstanding immediately prior to the First Merger Effective Time was automatically cancelled and ceased to exist in exchange for the right to receive one (1) newly issued PubCo Ordinary Share. Upon the consummation of the Business Combination on June 12, 2026, the Reporting Persons no longer beneficially owned any securities of HSPT, including any Ordinary Shares.
Item 5.	Interest in Securities of the Issuer
(a)	The responses to Items 7 - 13 of the cover pages of this Schedule 13D are incorporated herein by reference.
(b)	The responses to Items 7 - 13 of the cover pages of this Schedule 13D are incorporated herein by reference.
(c)	Other than the disposition of the shares as reported in this Schedule 13D, no actions in the ordinary shares were effected during the past sixty (60) days by the Reporting Persons.
(d)	N/A
(e)	As of June 12, 2026, the Reporting Persons ceased to beneficially own more than 5% of the issued and outstanding Ordinary Shares.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Items 4 of this Schedule 13D are hereby incorporated by reference into this Item 6.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended by adding the following to the end of the section: 7.1 Joint Filing Agreement, dated November 19, 2024 10.1 Securities Purchase Agreement by and among the Registrant and the sponsor, dated as of July 25, 2024. 10.2 Securities Transfer Agreement, among the Registrant, the sponsor and the directors, dated as of July 26, 2024 10.3 Securities Transfer Agreement, among the Registrant, the sponsor and the CFO, dated as of July 26, 2024 10.4 Private Units Subscription Agreement dated November 14, 2024 between the Sponsor and the Issuer. 10.5 Business Combination Agreement, dated May 9, 2025, by and among Horizon Space Acquisition II Corp., SL Bio Ltd, SL Science Holding Limited, CW Mega Limited, and WW Century Limited.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Horizon Space Acquisition II Sponsor Corp.

Signature:	/s/ Mingyu Li
Name/Title:	Sole Director
Date:	06/17/2026

Mingyu Li

Signature:	/s/ Mingyu Li
Name/Title:	Mingyu Li
Date:	06/17/2026

FAQ

What does this Schedule 13D/A amendment report for Horizon Space Acquisition II Corp. (HSPT)?

It reports that Horizon Space Acquisition II Sponsor Corp. and Mingyu Li now beneficially own zero HSPT ordinary shares, representing 0% of the class. The amendment is designated as a final, “exit” filing following completion of the business combination with SL Science Holding Limited on June 12, 2026.

Who are the reporting persons in this HSPT Schedule 13D/A filing?

The reporting persons are Horizon Space Acquisition II Sponsor Corp., a Cayman Islands exempted company that sponsored HSPT, and Mr. Mingyu Li. Mr. Li is the sponsor’s sole director, beneficially owns 50% of its outstanding shares, and is deemed to have voting and dispositive power over securities held by the sponsor.

What business combination led to the exit filing for HSPT on June 12, 2026?

On June 12, 2026, HSPT completed a business combination under a May 9, 2025 Business Combination Agreement with SL Science Holding Limited, CW Mega Limited, WW Century Limited, and SL Bio Ltd. HSPT and SL Bio became subsidiaries of SL Science Holding Limited following a two-step merger structure.

How were HSPT ordinary shares treated in the business combination described in this amendment?

Immediately before the first merger, each HSPT unit was split into one ordinary share and one right, and each right converted into one-tenth of an ordinary share. All resulting HSPT ordinary shares were then cancelled and exchanged for one newly issued PubCo ordinary share for each HSPT ordinary share.

Do Horizon Space Acquisition II Sponsor Corp. and Mingyu Li still hold any HSPT securities?

No. The cover page states that each reporting person beneficially owns 0.00 shares, representing 0% of HSPT’s ordinary shares. The amendment explains that, upon consummation of the June 12, 2026 business combination, the reporting persons no longer beneficially owned any HSPT securities, including ordinary shares.

What key agreements are referenced in this Horizon Space Acquisition II Corp. Schedule 13D/A?

The filing lists several agreements, including a Securities Purchase Agreement dated July 25, 2024, two Securities Transfer Agreements dated July 26, 2024, a Private Units Subscription Agreement dated November 14, 2024, and the Business Combination Agreement dated May 9, 2025 among HSPT, SL Bio Ltd. and related Cayman entities.